AdvEnzymes: consolidated profit rises in Q2 as share buyback is completed
AdvEnzymes reported higher consolidated revenue and profit for Q2 and closed its share buyback after using 99.99% of the approved amount.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
AdvEnzymes reported that consolidated revenue and net profit in Q2 were higher than in Q2 FY26. Consolidated net profit for the first half also increased. The company closed its buyback after using 99.99% of the approved size.
Standalone net profit for the first half, however, declined year on year. The information is based on TradingView, which cites an AI-generated summary of the original document.
why it matters
The consolidated growth and the completed buyback matter to the company's investors, but the drop in standalone first-half profit points to uneven performance across the group. The news concerns one company and has no notable effect on the broader market.
tags
instruments
sources
- ADVENZYMES: Q2 consolidated profit rose YoY as revenue advanced; the buyback closed at 99.99% of its cap — TradingView, 1 November 2026 at 14:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗